Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
Clinical trial NCT03820986 · COMPLETED
Trial details
- NCT number
- NCT03820986
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-12
- Primary completion
- 2023-01-18
- Enrollment
- 674
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.